These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30536701)

  • 21. Degradation of p53 by HPV16-E6 variants isolated from cervical cancer specimens of Moroccan women.
    Hadami K; Saby C; Dakka N; Collin G; Attaleb M; Khyatti M; Filali-Maltouf A; Morjani H; El Mzibri M
    Gene; 2021 Jul; 791():145709. PubMed ID: 33984442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma].
    Bian J; Yu X; Dong J; Zhao W; Zhou Y; Luan Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):271-3. PubMed ID: 15617346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo.
    Jung HS; Erkin OC; Kwon MJ; Kim SH; Jung JI; Oh YK; Her SW; Ju W; Choi YL; Song SY; Kim JK; Kim YD; Shim GY; Shin YK
    Int J Cancer; 2012 Apr; 130(8):1925-36. PubMed ID: 21630254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HPV16 infection regulates RASSF1A transcription mediated by p53.
    Lei Y; Hu C; Xu H; Tian Y
    Mol Med Rep; 2013 Aug; 8(2):413-8. PubMed ID: 23779024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PinX1, a novel target gene of p53, is suppressed by HPV16 E6 in cervical cancer cells.
    Wu G; Liu D; Jiang K; Zhang L; Zeng Y; Zhou P; Zhong D; Gao M; He F; Zheng Y
    Biochim Biophys Acta; 2014 Feb; 1839(2):88-96. PubMed ID: 24412852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HPV16 oncogene expression levels during early cervical carcinogenesis are determined by the balance of epigenetic chromatin modifications at the integrated virus genome.
    Groves IJ; Knight EL; Ang QY; Scarpini CG; Coleman N
    Oncogene; 2016 Sep; 35(36):4773-86. PubMed ID: 26876196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer.
    Yamato K; Yamada T; Kizaki M; Ui-Tei K; Natori Y; Fujino M; Nishihara T; Ikeda Y; Nasu Y; Saigo K; Yoshinouchi M
    Cancer Gene Ther; 2008 Mar; 15(3):140-53. PubMed ID: 18157144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma.
    Liu WL; Green N; Seymour LW; Stevenson M
    Cancer Gene Ther; 2009 Oct; 16(10):764-75. PubMed ID: 19363466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
    Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hsp90 up-regulates PD-L1 to promote HPV-positive cervical cancer via HER2/PI3K/AKT pathway.
    Zeng J; He SL; Li LJ; Wang C
    Mol Med; 2021 Oct; 27(1):130. PubMed ID: 34666670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.
    Sato N; Saga Y; Uchibori R; Tsukahara T; Urabe M; Kume A; Fujiwara H; Suzuki M; Ozawa K; Mizukami H
    Int J Oncol; 2018 Mar; 52(3):687-696. PubMed ID: 29344635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended effects of human papillomavirus 16 E6-specific short hairpin RNA on cervical carcinoma cells.
    Bai L; Wei L; Wang J; Li X; He P
    Int J Gynecol Cancer; 2006; 16(2):718-29. PubMed ID: 16681752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
    Spitkovsky D; Aengeneyndt F; Braspenning J; von Knebel Doeberitz M
    Oncogene; 1996 Sep; 13(5):1027-35. PubMed ID: 8806692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53.
    Au Yeung CL; Tsang WP; Tsang TY; Co NN; Yau PL; Kwok TT
    Oncol Rep; 2010 Dec; 24(6):1599-604. PubMed ID: 21042757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Degradation of p53 by natural variants of the E6 protein of human papillomavirus type 16.
    Yi JW; Jang M; Kim SJ; Kim SS; Rhee JE
    Oncol Rep; 2013 Apr; 29(4):1617-22. PubMed ID: 23404471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes.
    Zhou J; Li B; Peng C; Wang F; Fu Z; Zhou C; Hong D; Ye F; Lü W; Xie X
    Antiviral Res; 2013 May; 98(2):305-13. PubMed ID: 23523766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells.
    Munagala R; Kausar H; Munjal C; Gupta RC
    Carcinogenesis; 2011 Nov; 32(11):1697-705. PubMed ID: 21859835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel MLL5 isoform that is essential to activate E6 and E7 transcription in HPV16/18-associated cervical cancers.
    Yew CW; Lee P; Chan WK; Lim VK; Tay SK; Tan TM; Deng LW
    Cancer Res; 2011 Nov; 71(21):6696-707. PubMed ID: 21908553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Piwil2 is reactivated by HPV oncoproteins and initiates cell reprogramming via epigenetic regulation during cervical cancer tumorigenesis.
    Feng D; Yan K; Zhou Y; Liang H; Liang J; Zhao W; Dong Z; Ling B
    Oncotarget; 2016 Oct; 7(40):64575-64588. PubMed ID: 27602489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression‑independent manner in HPV‑positive human cervical cancer‑derived cells.
    Clemente-Soto AF; Salas-Vidal E; Milan-Pacheco C; Sánchez-Carranza JN; Peralta-Zaragoza O; González-Maya L
    Mol Med Rep; 2019 Mar; 19(3):2097-2106. PubMed ID: 30664221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.